China's Innovative Drug Industry: A Decade in Review (2015–2025)

Feb 24, 2026 08:00 CST Updated 08:00

Over the past decade, China’s innovative drug industry has experienced leapfrog development, undergoing a profound transformation from imitation and follow-on strategies to independent innovation, thereby emerging as an indispensable new force in the global biopharmaceutical sector. Today, the industry stands at a critical turning point driven by quality leadership, witnessing both a surge in innovative achievements and facing the significant challenge of moving up the value chain.

Over the past decade, numerous technical bottlenecks have been overcome, clinical gaps in multiple therapeutic areas have been filled, and frontier R&D directions have achieved synchronization with global standards. The quality and efficacy of domestically developed innovative drugs have gained widespread recognition. Meanwhile, significant breakthroughs in internationalization have been achieved, with independently developed products successfully entering the global market, breaking the monopoly of international giants. This has marked an initial leap from technology export to value leadership, completing a role transition from “market entrant” to “participant,” and even to “leader.”

Against this backdrop, on Saturday, February 28 at 19:00, VCBeat and Wei Jieyao jointly hosted the “China Innovative Medical Assets Living Room” Insights RelativityIssue 5,InvitedAssistant General Manager of Tianfeng Securities Research Institute, Consumer Industry ResearchResearch GroupDeputy Team Leader, Chief Pharmaceutical AnalystYang SongPeri-Encircle《201"5-2025 A Decade Review of China's Innovative Drug Industry"Topic Sharing.

Live Broadcast Introduction

海报.jpg

Guest Introduction

Guest: Yang Song

Tianfeng Securities Research Institute

Assistant to the General Manager, Deputy Head of the Consumer Industry Research Group, Chief Healthcare Analyst

Master’s degree from the School of Pharmaceutical Sciences, Peking University / Dual degree in Economics from CCER; Member of the Medical Insurance Professional Committee of the China Social Security Association; Nearly a decade of experience primarily focused on research in the biopharmaceutical industry and capital markets.

Shared Topics

A Decade in Review: China’s Innovative Drug Industry (2015–2025)

● A Decade of Policy: Regulatory Reforms Reshape the Industrial Ecosystem; The Development of Innovative Drugs Is Inseparable from Policy Support;

● A Decade of Industry Evolution: From Imitation and Following to Global Participation;

● A Decade of Market Trends: Capital Cycles and Value Reconstruction;

● Looking Ahead: A Paradigm Shift in Innovative Drug Investment.

Live Broadcast Program Introduction

China Innovative Healthcare Assets Reception Hall

“China’s Innovative Healthcare Asset Lounge” is an online live-streaming program launched by VCBeat, positioned at its core to “connect China’s innovative healthcare assets with global buyers.” The program focuses on high-quality asset transactions in fields such as innovative drugs, high-end medical devices, and digital health, aiming to build a professional platform for “presentation, communication, and matchmaking” tailored to strategic, financial, and industrial buyers. With the goal of “unlocking the value of China’s innovative assets and facilitating efficient transactions,” the program helps buyer groups capture opportunities in high-quality assets through precise supply-demand matching, analysis of transaction logic, and sharing of practical experience. Meanwhile, it promotes the conversion and retention of local innovative assets, contributing to the ecosystem development of the Global Life and Health Innovative Asset Buyers Alliance.

Live Stream Channel

Scan the QR code to reserve your spot for the live broadcast

List Application

Call for Nominations Launched for the 2026 Future Healthcare Top 100!

The 2026 Top 100 Future Healthcare Companies selection is anchored in the core direction of “Innovation, Transaction, and Empowerment in China’s Healthcare Industry,” achieving a comprehensive upgrade of the evaluation system. This edition features two core components: the 2026 Top 100 Future Healthcare Companies List and the 2026 Top 100 Future Healthcare Companies Awards.

申报通道.jpg

Scan the QR code to view application details